-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the full abstracts of the six studies (covering clinical research, translational research and meta-analysis) of the self-developed Velisign® (opatisumimab, anti-PD-L1/4-1BB bispecific antibody) and LBL-034 (GPRC5D/CD3 bispecific T-cell connector, TCE) were published on the official website of the 2026 European Society of Medical Oncology (ESMO 2026). This data collection shows trends in long-lasting relief and prolonged survival benefits of Velisign® in multiple immune “cold tumors”, supports its potential as a pan-tumor therapy, and highlights the differentiation capabilities of the company's X-body and TCE technology platforms. Notably, three studies, Verisign® and LBL-034, were selected for ESMO's preferred oral presentation in 2026, and one study was selected as the Breakthrough Summary (LBA). Detailed and updated data on these studies will be released during ESMO's oral report in 2026.

Zhitongcaijing·10/19/2026 12:25:16
Listen to the news
Zhitong Finance App News, Weilizhibo-B (09887.HK) announced that the full abstracts of the six studies (covering clinical research, translational research and meta-analysis) of the self-developed Velisign® (opatisumimab, anti-PD-L1/4-1BB bispecific antibody) and LBL-034 (GPRC5D/CD3 bispecific T-cell connector, TCE) were published on the official website of the 2026 European Society of Medical Oncology (ESMO 2026). This data collection shows trends in long-lasting relief and prolonged survival benefits of Velisign® in multiple immune “cold tumors”, supports its potential as a pan-tumor therapy, and highlights the differentiation capabilities of the company's X-body and TCE technology platforms. Notably, three studies, Verisign® and LBL-034, were selected for ESMO's preferred oral presentation in 2026, and one study was selected as the Breakthrough Summary (LBA). Detailed and updated data on these studies will be released during ESMO's oral report in 2026.